Biohaven Reports First Quarter 2021 Financial Results and Recent Business Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Biohaven Pharma (BHVN) Misses Q1 EPS by 15c, Revenues Beat
May 10, 2021 7:33 AM EDTBiohaven Pharma (NYSE: BHVN) reported Q1 EPS of ($2.97), $0.15 worse than the analyst estimate of ($2.82). Revenue for the quarter came in at $43.82 million versus the consensus estimate of $40.63 million.
Vlad Coric, M.D., Chief Executive Officer of Biohaven commented, "NURTEC ODT's performance, with its... More
